Project Grant R01CA317672
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $510K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hanover, NH 03755, USA
Similar Awards
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $134,919 on April 14, 2026, under the Cancer Research Manpower program (CFDA 93.398) to establish ethical standards for informed consent and counseling in multi-cancer early detection testing. Dr. Eric Blackstone, a bioethics research fellow, will conduct three coordinated research aims. Aim 1 evaluates patient comprehension of key multi-cancer early detection information and patient experiences with informed consent and...
- The National Cancer Institute awarded the University of Rochester $345,413 on June 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized clinical trial testing interventions to increase lung cancer screening uptake among high-risk emergency department patients. The project develops and evaluates a low-cost, scalable intervention deployable in any emergency department with a regionally referrable lung cancer screening program. The trial uses a...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $745,458 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a digital intervention that uses patient portals to improve person-centered communication between cancer patients and oncology clinicians. The PERSON intervention comprises three automated, scalable components: a portal-enabled assessment tool (a 14-item questionnaire capturing patient information...
- The National Cancer Institute awarded Dartmouth-Hitchcock Clinic $633,819 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate advanced imaging techniques for laser interstitial thermal therapy (LITT) in the treatment of spinal metastases. The project addresses two critical technical barriers limiting clinical adoption of LITT for spinal tumors: inaccuracies in MRI thermometry caused by motion artifacts from respiration and cardiac...
- The National Cancer Institute awarded The MGH Institute of Health Professions, Inc. $696,498 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and optimize a multicomponent intervention for improving functional recovery and participation in life roles among breast cancer survivors. The research uses the Multiphase Optimization Strategy (MOST) framework to systematically test three remotely delivered intervention components: priority elicitation to...
- The National Institutes of Health National Cancer Institute awarded Weill Medical College of Cornell University $595,632 on July 17, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to optimize prostate cancer screening decision-making among men age 70 and older. The project uses mixed-methods research to understand how prostate cancer screening cessation should be tailored to patient health status in this population. Current evidence shows that while prostate cancer...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded the University of Pittsburgh $649,620 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to examine Medicare Advantage plan impacts on cancer care access, quality, and outcomes for older adults. The project investigates whether Medicare Advantage's limited provider networks create barriers to timely specialty care for patients with the four most prevalent cancers—breast, colorectal, lung, and prostate. The research employs...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $766,699 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop, implement, and test a family-centered web-based intervention for cancer risk communication in children and adolescents with genetic predisposition to cancer. The deliverable is Family RISE (Risk Information and Screening Education), a web-based platform designed to communicate genetic cancer risk information to...